<DOC>
	<DOCNO>NCT00028067</DOCNO>
	<brief_summary>The purpose study compare atazanavir nelfinavir ( NFV ) treatments ability reduce viral load .</brief_summary>
	<brief_title>A Comparison Atazanavir Nelfinavir , Each Combination With 2 NRTIs , Patients Who Have Failed Treatments Without Protease Inhibitor</brief_title>
	<detailed_description>In double-blind , double-placebo , randomize , 2-arm study , atazanavir NFV give combination 2 open-label nucleoside reverse transcriptase inhibitor ( NRTIs ) 48 week . Patients assign atazanavir receive placebo capsule identical size appearance NFV . Patients assign NFV receive placebo capsule identical size appearance atazanavir . HIV level monitor .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Have viral load 1000 copies/ml within 3 week randomization . Have CD4 cell count 50 cells/mm3 within 3 week prior randomization . Are least 16 year old ( minimum age local requirement ) . Have 16 week therapy nonnucleoside reverse transcriptase inhibitor ( NNRTI ) and/or nucleoside reverse transcriptase inhibitor ( NRTI ) . Use effective barrier method contraception . Give write informed consent . Are available followup least 52 week . Exclusion Criteria Patients may eligible study : Have use protease inhibitor ( PI ) treatment 7 day within 30 day prior screen . Have newlydiagnosed HIVrelated infection medical condition require relatively short intense therapy time enrollment . Have hepatitis 30 day study . Patients longterm hepatitis eligible liver function meet certain requirement . Are unable demonstrate responsiveness provide NRTI . Have previous expect need therapy agent may cause damage nerve tissue , pancreas , liver , bone marrow , cell within 3 month study start . Use much alcohol drug able follow study therapy ; use enough increase risk develop pancreatitis chemical hepatitis . Have severe diarrhea within 30 day prior study entry . Are pregnant breastfeeding . Have history hemophilia . Have history sign bilateral peripheral neuropathy . Have cardiomyopathy . Have certain heart problem . Can tolerate oral medication . Have problem would interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Viral Load</keyword>
	<keyword>BMS 232632</keyword>
</DOC>